ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC

CHICAGO 2025

Breast Cancer

LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC

SABCS 2025

Breast Cancer

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ESMO 2025

Breast Cancer

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

SABCS 2025

Breast Cancer

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

SPECIAL REPORT

Gynecologic Cancer

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Genitourinary Cancer

Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer

Lung, Respiratory and Thoracic Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Lung Cancer

Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S

doi: 10.1016/j.lungcan.2025.108855

Lung, Respiratory and Thoracic Cancer

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung Cancer

Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S

doi: 10.1016/j.lungcan.2025.108422

Related content

LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study